Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1205 • ACR Convergence 2021
Predictors of Discordance Between Patient and Physician Global Assessment in Patients with Rheumatoid Arthritis
Gulay Alp¹, Dilek Solmaz², Haluk Cinaklı¹, Elif Ediboglu¹, Eda OTMAN¹, Esra Erpek¹ and Servet Akar², ¹Izmir Katip Celebi University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, İzmir, Turkey, ²Izmir Katip Celebi University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Izmir, Turkey
Background/Purpose: The patient’s global assessment (PGA) and physician global assessment (PhGA) are important outcomes and commonly used in rheumatoid arthritis (RA) clinical practice. Both measures…
Abstract Number: 1221 • ACR Convergence 2021
Association of Neutrophil Lymphocyte and Platelet Lymphocyte Ratios with Joint Inflammation in Rheumatoid Arthritis
Diyu Pearce-Fisher¹, Dana Orange², Bella Mehta³, Deanna Jannat-Khah¹ and Susan Goodman¹, ¹Hospital for Special Surgery, New York, NY, ²The Rockefeller University, New York, NY, ³Hospital for Special Surgery, Weill Cornell Medicine, New York, NY
Background/Purpose: It can be challenging to determine whether rheumatoid arthritis (RA) patients who require arthroplasty have ongoing inflammation, in addition to damage in the affected…
Abstract Number: 1237 • ACR Convergence 2021
Predictors of Response: Baseline Characteristics and Early Treatment Responses Associated with Achievement of Remission and Low Disease Activity Among Upadacitinib-Treated Patients with Rheumatoid Arthritis
Arthur Kavanaugh¹, Zoltan Szekanecz², Edward Keystone³, Andrea Rubbert-Roth⁴, Stephen Hall⁵, Ricardo Xavier⁶, Joaquim Pereira⁷, In-Ho Song⁸, Naomi Martin⁹, Yanna Song⁸, Samuel Anyanwu⁸ and Peter Nash¹⁰, ¹Division of Rheumatology, Allergy and Immunology, Department of Medicine, University of California San Diego, La Jolla, CA, ²Division of Rheumatology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary, ³Keystone Consulting Enterprises Inc., Toronto, ON, Canada, ⁴Kantonspital St Gallen, St.Gallen, Switzerland, ⁵Emeritus Research and Monash University, Melbourne, Australia, Melbourne, Australia, ⁶Departamento de Reumatologia, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ⁷Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte and Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisbon Academic Medical Centre, Lisbon, Portugal, ⁸AbbVie Inc., North Chicago, IL, ⁹AbbVie Inc., Saint-Laurent, QC, Canada, ¹⁰Griffith University, Brisbane, Australia
Background/Purpose: Early prediction of response to treatment with upadacitinib (UPA) 15 mg once daily (QD) could help optimize therapy in patients (pts) with RA.1-4 The…
Abstract Number: 1253 • ACR Convergence 2021
Acupuncture in Rheumatoid Arthritis Activity
Diana Seixas¹, Fátima Farinha², Marcos Pacheco da Fonte³, Manuel Laranjeira¹ and Marília Rua⁴, ¹ICBAS, Porto, Portugal, ²CHUP-HSA, Porto, Portugal, ³CHEDV, Santa Maria da Feira, Portugal, ⁴University Aveiro, Aveiro, Portugal
Background/Purpose: High activity rates of Rheumatoid Arthritis (RA) lead to an increased risk of mortality. RA patients have a high incidence of comorbidities, associated with…
Abstract Number: 1507 • ACR Convergence 2021
Role of CD4+ T Cells in the Pathogenesis of RA: Immunization with Citrullinated T Cell Epitopes Is Sufficient to Induce Immunological and Clinical Manifestations of Arthritis in DR4-Transgenic Mice
Elena Tonti¹, Bhargavi Duvvuri², Sudeshna Dhar¹, Derek Haaland³, Maggie Larche¹ and Mark Larché¹, ¹McMaster University, Hamilton, ON, Canada, ²University of Washington, Seattle, WA, ³McMaster University, Hamilton, Ontario and The Waterside Clinic, Oro Medonte, ON, Canada
Background/Purpose: Although the etiology of rheumatoid arthritis (RA) remains unclear, existing research suggests a complex interplay of both genetic and environmental factors. Citrullinated proteins/peptides, and…
Abstract Number: 1652 • ACR Convergence 2021
Symptom Burden in Anti-citrullinated Protein Antibody Positive Individuals At-risk for Rheumatoid Arthritis Is Changing over Time and Comparable to Patients with Early Rheumatoid Arthritis
Paul Studenic¹, Alexandra Circiumaru², Daniel Aletaha³, Katerina Chatzidionysiou⁴, Anca Catrina⁵ and Aase Haj Hensvold⁶, ¹Karolinska Institute; & Medical University of Vienna, Stockholm, Sweden, ²Division for Rheumatology, Karolinska Institutet; Center for Rheumatology, Academic Specialist Center, Stockholm Region, Stockholm, Sweden, ³Medical University Vienna, Vienna, Austria, ⁴Karolinska Institute, Division of Rheumatology; & Karolinska University Hospital, Rheumatology Unit, Stockholm, Sweden, ⁵Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden, ⁶Karolinska Institutet, Division for Rheumatology; & Center for Rheumatology, Academic Specialist Center, Stockholm Region, Stockholm, Sweden
Background/Purpose: Symptom burden in individuals at risk for developing rheumatoid arthritis (RA) - positive for anti-citrullinated peptide antibodies (ACPA) and musculoskeletal complaints - has not…
Abstract Number: 1668 • ACR Convergence 2021
Unmet Need in Early Rheumatoid Arthritis – Why Do Some Patients Do Badly Despite Modern Treat-to-target Strategies of Care? Results from the Scottish Early RA (SERA) Inception Cohort
Elizabeth Clarke¹, Claire Wood¹, Alistair Tindell¹, Kay Graham¹, Alasdair McIntosh², Fraser Morton² and Duncan Porter³, ¹NHS Greater Glasgow and Clyde, Glasgow, United Kingdom, ²University of Glasgow, Glasgow, United Kingdom, ³University of Glasgow, Bearsden, United Kingdom
Background/Purpose: ‘Treat to target’ strategies of care have significantly improved outcomes in people with early rheumatoid arthritis; nonetheless, a significant proportion of patients have impaired…
Abstract Number: 1684 • ACR Convergence 2021
Incidence of Infections in Patients Aged ≥ 50 Years with RA and ≥ 1 Additional Cardiovascular Risk Factor: Results from a Phase 3b/4 Randomized Safety Study of Tofacitinib vs TNF Inhibitors
Andra R Bălănescu¹, Gustavo Citera², Virginia Pascual-Ramos³, Carol A Connell⁴, David Gold⁵, All-shine Chen⁴, Harry Shi⁶, Andrea B Shapiro⁷, Janet Pope⁸ and Hendrik Schulze-Koops⁹, ¹“Carol Davila” University of Medicine and Pharmacy, Department of Internal Medicine and Rheumatology “Sf. Maria” Hospital, Bucharest, Romania, ²Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ³Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc, Montréal, QC, Canada, ⁶Pfizer Inc, Collegeville, PA, ⁷Pfizer Inc, Peapack, NJ, ⁸University of Western Ontario, London, ON, Canada, ⁹Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, University of Munich, Munich, Germany
Background/Purpose: Previous clinical trial and real-world data suggest that risk of serious infection events (SIEs) and opportunistic infections (OIs) is similar with tofacitinib 5 mg…
Abstract Number: 1700 • ACR Convergence 2021
Pharmacokinetic Boosting to Enable Once-Daily Reduced Dose Tofacitinib
Céleste van der Togt¹, Lise Verhoef², Nathan den Broeder³, Rob ter Heine³, Bart van den Bemt⁴ and Alfons den Broeder⁵, ¹Sint Maartenskliniek, Ubbergen, Gelderland, Netherlands, ²Sint Maartenskliniek, Nijmegen, Netherlands, ³Radboud University Medical Centre, Nijmegen, Gelderland, Netherlands, ⁴Sint Maartenskliniek; Radboud University Medical Center, Ubbergen, Netherlands, ⁵Sint Maartenskliniek, Nijmegen, Gelderland, Netherlands
Background/Purpose: Tofacitinib is an effective, yet costly, drug for treatment of RA and PsA. Tofacitinib is metabolized mainly by the cytochrome P450-enzyme CYP3A4, and the…
Abstract Number: 1893 • ACR Convergence 2021
“From Where I Stand”: Using Multiple Anchors Yields Different Benchmarks for Meaningful Improvement and Worsening in the Rheumatoid Arthritis Flare Questionnaire (RA-FQ)
Susan Bartlett¹, Vivian Bykerk², Orit Schieir³, Marie-France Valois¹, Louis Bessette⁴, Gilles Boire⁵, Glen Hazlewood⁶, Carol Hitchon⁷, Edward Keystone⁸, Janet Pope⁹, Diane Tin¹⁰, Carter Thorne¹¹, Clifton Bingham¹² and CATCH Investigators¹³, ¹McGill University, Montréal, QC, Canada, ²Hospital for Special Surgery, New York, NY, ³Canadian Early Arthritis Cohort Study, Montréal, QC, Canada, ⁴Centre de l'Ostoporose et de Rhumatologie de Qubec, Québec City, QC, Canada, ⁵Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁶University of Calgary, Calgary, AB, Canada, ⁷University of Manitoba, Winnipeg, MB, Canada, ⁸Keystone Consulting Enterprises Inc., Toronto, ON, Canada, ⁹University of Western Ontario, London, ON, Canada, ¹⁰The Arthritis Program Research Group, Newmarket, ON, Canada, ¹¹Southlake Regional Health Centre, Newmarket, ON, Canada, ¹²Johns Hopkins University, Baltimore, MD, ¹³Canadian Early Arthritis Cohort Investigators, Toronto, ON, Canada
Background/Purpose: The RA-FQ is a patient-reported measure of current disease activity in RA that can be used to identify disease flares. The RA-FQ queries pain,…
Abstract Number: PP07 • ACR Convergence 2021
How Online Spanish-Language Resources Got Me and My RA Through the COVID-19 Pandemic
Wigna Cruz, Puerto Rico
Background/Purpose: I was experiencing joint pain especially in my wrists, which led me to see my physician for testing. Initially I was misdiagnosed with lupus.…
Abstract Number: 0013 • ACR Convergence 2021
Cyclin Dependent Kinase 4 and 6 Determine the Cytokine Responsiveness by Stabilizing JUN in Rheumatoid Arthritis Synovial Fibroblasts
Tadashi Hosoya¹, Tetsuya Saito², Hiroyuki Baba², Nao Tanaka², Seiji Noda², Yoji Komiya², Yasuhiro tagawa², Akio Yamamoto² and Shinsuke Yasuda², ¹Tokyo Medical and Dental University(TMDU), Tokyo, Japan, ²Tokyo Medical and Dental University (TMDU), Tokyo, Japan
Background/Purpose: Although current inflammation-targeted therapy improved the outcome of patients with rheumatoid arthritis (RA), the achievement of complete disease remission was still challenging. Since synovial…
Abstract Number: 0031 • ACR Convergence 2021
A New Pharmacostatistical Model to Assess MTX-adherence in RA Patients
Marion Geoffroy¹, Claire Gozalo², Loic Pauvele², Elise Abboud², Zoubir Djerada³ and Jean hugues Salmon⁴, ¹CHU Reims, France, REIMS, France, ²CHU Reims, Reims, France, ³CHU Riems, Reims, France, ⁴Rheumatology, CHU Maison blanche, Reims, Reims, France
Background/Purpose: Methotrexate (MTX) is the first-line therapy for rheumatoid arthritis (RA). While therapeutic adherence is essential to the successful management of the patient, an estimated…
Abstract Number: 0088 • ACR Convergence 2021
Evaluation of Patient Characteristics and Clinical Outcomes Among SARS‑CoV‑2‑Diagnosed Patients with and Without RA or PsA Treated with Systemic Therapies: A Retrospective Cohort Study Using US Optum® COVID-19 Electronic Health Record Data
Jeffrey Curtis¹, Xiaofeng Zhou², Jinoos Yazdany³, Philip Robinson⁴, Yan Chen², Ann Madsen², Jamie Geier² and Birgitta Benda², ¹Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ²Pfizer Inc, New York, NY, ³University of California San Francisco, San Francisco, CA, ⁴Faculty of Medicine, The University of Queensland, Herston, Australia
Background/Purpose: Patients with chronic rheumatic diseases are considered to be at increased risk for some infections, with prescribed immunomodulatory (IM) therapies increasing this risk further.…
Abstract Number: 0168 • ACR Convergence 2021
A Crowdsourcing Approach to Develop Machine Learning Models to Quantify Radiographic Joint Damage in Rheumatoid Arthritis
Dongmei Sun¹, Robert Allaway², Jelai Wang¹, Verena Chung², Thomas Yu², Isaac Dimitrovsky³, Lars Ericson⁴, Yuanfang Guan⁵, Ariel Israel⁶, Hongyang Li⁵, Michael Mason⁷, Alex Olar⁸, Balint Pataki⁸, Stephanie Ledbetter¹, RA2 DREAM Challenge Community⁹, Gustavo Stolovitzky¹⁰, Justin Guinney², Percio Gulko¹¹, Mason Frazier¹, James Costello¹², Jake Chen¹ and S. Louis Bridges, Jr.¹³, ¹University of Alabama at Birmingham, Birmingham, AL, ²Sage Bionetworks, Seattle, WA, ³Self-employed, New York, NY, ⁴Catskills Research, Charlotte, NC, ⁵University of Michigan, Ann Arbor, MI, ⁶Hebrew University, Jerusalem, Israel, ⁷BMS, Seattle, WA, ⁸Eotvos Lorand University, Budapest, Hungary, ⁹RA2 DREAM Challenge Community, New York, NY, ¹⁰IBM, New York, NY, ¹¹Icahn School of Medicine at Mount Sinai, New York, NY, ¹²University of Colorado Anschutz Medical Campus, Denver, CO, ¹³Hospital for Special Surgery, New York, NY
Background/Purpose: Rheumatoid arthritis (RA) is a common chronic autoimmune disease characterized by inflammation of the synovium, leading to joint space narrowing and osseous erosions. The…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].